Vol. 5 No. 5 (2025)
Reimbursement Reviews

Momelotinib (Ojjaara)

decorative image of the issue cover

Published May 27, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses momelotinib (Ojjaara), 200 mg, 150 mg, and 100 mg tablets.
  • Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera MF or post essential thrombocythemia MF who have moderate to severe anemia.